[Form 4] Indaptus Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Indaptus Therapeutics Co-Chief Executive Officer and director Jeffrey Meckler reported derivative warrant transactions tied to a board-approved repricing. On February 11, 2026, previously held warrants were disposed of back to the company and replacement warrants were acquired on a direct ownership basis.

The transactions cover several warrant series exercisable for common stock, with the board unilaterally reducing the per-share exercise price of all affected warrants to $1.75 while leaving all other terms unchanged. Following the dispositions and matching acquisitions, Meckler directly holds new warrants for 3,033, 1,519, and 12,136 underlying shares at the revised exercise price.

The filing also notes that on June 26, 2025, Indaptus implemented a 1-for-28 reverse stock split of its common stock, and all warrant amounts in the report reflect this adjustment.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Meckler Jeffrey A

Role Co-Chief Executive Officer

Type	Security	Shares	Price	Value
Disposition	Warrants (right to buy)	3,033	$0.00	--
Grant/Award	Warrants (right to buy)	3,033	$0.00	--
Disposition	Warrants (right to buy)	1,519	$0.00	--
Grant/Award	Warrants (right to buy)	1,519	$0.00	--
Disposition	Warrants (right to buy)	12,136	$0.00	--
Grant/Award	Warrants (right to buy)	12,136	$0.00	--

Holdings After Transaction: Warrants (right to buy) — 0 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meckler Jeffrey A

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC

3 COLUMBUS CIRCLE, 15TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (right to buy)	$47.6	02/11/2026		D			3,033	08/08/2024	08/08/2029	Common Stock	3,033	(1)	0	D
Warrants (right to buy)	$1.75	02/11/2026		A		3,033		02/11/2026	08/08/2029	Common Stock	3,033	(1)	3,033	D
Warrants (right to buy)	$29.4	02/11/2026		D			1,519	11/25/2024	11/25/2029	Common Stock	1,519	(1)	0	D
Warrants (right to buy)	$1.75	02/11/2026		A		1,519		02/11/2026	11/25/2029	Common Stock	1,519	(1)	1,519	D
Warrants (right to buy)	$8.3	02/11/2026		D			12,136	07/27/2025	07/27/2030	Common Stock	12,136	(1)	0	D
Warrants (right to buy)	$1.75	02/11/2026		A		12,136		02/11/2026	07/27/2030	Common Stock	12,136	(1)	12,136	D

Explanation of Responses:

1. Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.

Remarks:

On June 26, 2025, the Company effected a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.

	/s/ Jeffrey Meckler	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.